| Melanie Jo Drake, MD | |
|
777 N Raymond St, Boise, ID 83704-9251 | |
| (208) 514-2500 | |
| (208) 375-2217 |
| Full Name | Melanie Jo Drake |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 8 Years |
| Location | 777 N Raymond St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801236575 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | M-15195 (Idaho) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Full Circle Health, Inc. | 6709986797 | 93 |
News Archive
Here the research team tested a safe and well-established microbe-based immune adjuvant to restore immune homeostasis and counteract inflammation-associated obesity in animal models.
Despite numerous advances in oncology since the War on Cancer began, many patients develop resistance to standard therapies and eventually relapse. Moffitt Cancer Center researchers hope to improve treatment outcomes with development of a novel therapeutic strategy, called adaptive therapy, which is based on evolutionary principals and aims to keep resistant cells in check by maintaining a population of chemo-sensitive cells.
Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.
Changes in the endocannabinoid system may have important implications for psychiatric and addiction disorders. This brain system is responsible for making substances that have effects on brain function which resemble those of cannabis products, e.g., marijuana.
› Verified 3 days ago
| Entity Name | Full Circle Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841490075 PECOS PAC ID: 6709986797 Enrollment ID: O20070924000618 |
News Archive
Here the research team tested a safe and well-established microbe-based immune adjuvant to restore immune homeostasis and counteract inflammation-associated obesity in animal models.
Despite numerous advances in oncology since the War on Cancer began, many patients develop resistance to standard therapies and eventually relapse. Moffitt Cancer Center researchers hope to improve treatment outcomes with development of a novel therapeutic strategy, called adaptive therapy, which is based on evolutionary principals and aims to keep resistant cells in check by maintaining a population of chemo-sensitive cells.
Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.
Changes in the endocannabinoid system may have important implications for psychiatric and addiction disorders. This brain system is responsible for making substances that have effects on brain function which resemble those of cannabis products, e.g., marijuana.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melanie Jo Drake, MD 777 N Raymond St, Boise, ID 83704-9251 Ph: (208) 514-2500 | Melanie Jo Drake, MD 777 N Raymond St, Boise, ID 83704-9251 Ph: (208) 514-2500 |
News Archive
Here the research team tested a safe and well-established microbe-based immune adjuvant to restore immune homeostasis and counteract inflammation-associated obesity in animal models.
Despite numerous advances in oncology since the War on Cancer began, many patients develop resistance to standard therapies and eventually relapse. Moffitt Cancer Center researchers hope to improve treatment outcomes with development of a novel therapeutic strategy, called adaptive therapy, which is based on evolutionary principals and aims to keep resistant cells in check by maintaining a population of chemo-sensitive cells.
Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.
Changes in the endocannabinoid system may have important implications for psychiatric and addiction disorders. This brain system is responsible for making substances that have effects on brain function which resemble those of cannabis products, e.g., marijuana.
› Verified 3 days ago
Dr. Michael E. Estess, M. D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1471 Shoreline Dr, Suite 119, Boise, ID 83702 Phone: 208-345-2630 Fax: 208-345-6504 | |
John Carr, PMHNP Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1000 N Curtis Rd Ste 202, Boise, ID 83706 Phone: 208-283-7314 | |
Eric A Simmons, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 335 Allumbaugh St, Boise, ID 83704 Phone: 208-376-1611 Fax: 208-658-1753 | |
Dr. Gary Falk, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 500 W Fort St, Boise Vamc, Boise, ID 83702 Phone: 208-422-1108 | |
Karen Porth, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1072 N Liberty Street, Ste 303, Boise, ID 83704 Phone: 208-367-2800 Fax: 208-367-7111 | |
Ramon R Quijano, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 444 W Fort St., Fl 2, Boise, ID 83702 Phone: 208-422-1018 | |
Barbara J. Hagen, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 413 Allumbaugh St Ste 101, Boise, ID 83704 Phone: 208-323-1125 Fax: 208-323-9604 |